Registrations are open for the 1st GlycanTrigger Patients Symposium, an important event we are co-organising together with the Portuguese Society for Innovation (SPI), focused on collaborative discussions around strategies for predicting and preventing IBD.
We’re excited to present the latest issue of the EFCCA Magazine, now with a refreshed design! Inside, you’ll find an exclusive interview with Professor James Lee, who shares insights on his groundbreaking research into the causes of Inflammatory Bowel Disease (IBD).
EFCCA is excited to introduce a series of webinars, workshops and initiatives to be launched after the summer break.
We are pleased to announce the release of two significant reports that highlight our continuous efforts and achievements in advocating for improved IBD care and quality of life worldwide.
From 7 to 9 June 2024, Brussels hosted the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) General Assembly, representing a significant event for our organisation.
We are delighted to present to you the EFCCA PROJECTS DIGEST. This newsletter will include information regarding the 5 Horizon Europe projects, 2 Horizon 2020 projects, and other projects that EFCCA is presently engaged in. The PROJECTS DIGEST will be published every 2-3 months, and we trust it will serve as a valuable resource for delving deeper into our ongoing research initiatives.
We take great pleasure in informing you that EFCCA is one of the 12 partners coming from 9 countries of the consortium for the miGut-Health Project, which has been selected for European funding under the Horizon Europe framework. This project will strive to empower people living with IBD by creating state-of-the-art strategies for early disease prediction, prevention, and health monitoring. This will be achieved through data-driven approaches, personalised preventive interventions (such as nutritional changes), and innovative eHealth solutions.
October 2024
This study investigates the real-world effectiveness of Filgotinib (FIL), an oral JAK1 preferential inhibitor, in patients with ulcerative colitis (UC). While the clinical efficacy of FIL has been established in the SELECTION trial, real-world data has been limited.
On 12 October 2024, EFCCA organised a conference during UEG Week (Vienna) titled: "How can patients play a crucial role in medicines-related decision-making? An open dialogue with stakeholders and the presentation of the EFCCA HTA Guidebook."
We’re excited to present the latest issue of the EFCCA Magazine, now with a refreshed design! Inside, you’ll find an exclusive interview with Professor James Lee, who shares insights on his groundbreaking research into the causes of Inflammatory Bowel Disease (IBD).